Bayer gains approval of Factor XIa inhibitor asundexian to reduce stroke risk

Jonathan Block

• The US FDA on Monday approved Bayer's (BAYRY) Sunharbo (asundexian) for secondary stroke prevention in patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack
• The first-in-class Factor XIa inhibitor is taken in combination with antiplatelet therapy.
• Approval was based

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.